Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy

References

• Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. Journal of Immunotherapy Emphasis Tumor Immunology 1995; 17: 71–77
   PubMed Web of Science ®Google Scholar
• Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W, Favrot M. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Human Gene Therapy 1998; 9: 2481–2492
   PubMed Web of Science ®Google Scholar
• Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. International Journal of Oncology 1999; 15: 769–773
   PubMed Web of Science ®Google Scholar
• Golab J, Zagozdzon R. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). International Journal of Molecular Medicine 1999; 3: 537–544
   PubMed Web of Science ®Google Scholar
• Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang NS, Mahvi DM. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Molecular Cancer Therapy 2002; 1: 949–957
   PubMed Web of Science ®Google Scholar
• Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villarreal LP, Black KL, Yu JS. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Therapy 2002; 9: 9–15
   PubMed Web of Science ®Google Scholar
• Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999; 93: 1612–1621
   PubMed Web of Science ®Google Scholar
• Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. Journal of the National Cancer Institute 1995; 87: 581–586
   PubMed Web of Science ®Google Scholar
• Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Research 2000; 60: 1111–1116
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WM. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. Journal of Clinical Investigations 1998; 101: 1441–1452
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. Journal of Experimental Medicine 1989; 170: 827–845
   PubMed Web of Science ®Google Scholar
• Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunology 1992; 143: 127–142
   PubMed Web of Science ®Google Scholar
• Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. European Journal of Immunology 1997; 27: 1958–1965
   PubMed Web of Science ®Google Scholar
• Pham-Nguyen KB, Yang W, Saxena R, Thung SN, Woo SL, Chen SH. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. International Journal of Cancer 1999; 81: 813–819
   PubMed Web of Science ®Google Scholar
• Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, Ito M, Yagita H, Okumura K. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. European Journal of Immunology 1999; 29: 1390–1396
   PubMed Web of Science ®Google Scholar
• Watanabe M, Fenton RG, Wigginton JM, McCormick KL, Volker KM, Fogler WE, Roessler PG, Wiltrout RH. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production. Journal of Immunology 1999; 163: 1943–1950
   PubMed Web of Science ®Google Scholar
• Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Therapy 2000; 7: 826–838
   PubMed Web of Science ®Google Scholar
• Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623–1626
   PubMed Web of Science ®Google Scholar
• Zilocchi C, Stoppacciaro A, Chiodoni C, Parenza M, Terrazzini N, Colombo MP. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. Journal of Experimental Medicine 1998; 188: 133–143
   PubMed Web of Science ®Google Scholar
• North RJ, Kirstein DP. T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. Journal of Experimental Medicine 1977; 145: 275–292
   PubMed Web of Science ®Google Scholar
• Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. Journal of Experimental Medicine 1978; 148: 1560–1569
   PubMed Web of Science ®Google Scholar
• Le HN, Lee NC, Tsung K, Norton JA. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. Journal of Immunology 2001; 167: 6765–6772
   PubMed Web of Science ®Google Scholar
• Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8+ T-cell immunity. Cancer Gene Therapy 1998; 5: 321–330
   PubMed Web of Science ®Google Scholar
• Segal JG, Lee NC, Tsung YL, Norton JA, Tsung K. The role of IFN-gamma in rejection of established tumors by IL-12: source of production and target. Cancer Research 2002; 62: 4696–4703
   PubMed Web of Science ®Google Scholar
• Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. Journal of Immunology 1994; 153: 1697–1706
   PubMed Web of Science ®Google Scholar
• Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. International Immunology 1995; 7: 1135–1145
   PubMed Web of Science ®Google Scholar
• Yu WG, Yamamoto N, Takenaka H, Mu J, Tai XG, Zou JP, Ogawa M, Tsutsui T, Wijesuriya R, Yoshida R, Hermann S, Fujiwara H, Hamaoka T. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. International Immunology 1996; 8: 855–865
   PubMed Web of Science ®Google Scholar
• Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. Journal of Immunology 1998; 160: 1369–1377
   PubMed Web of Science ®Google Scholar
• Manetti R, Gerosa F, Giudizi MG, Biagiotti R, Parronchi P, Piccinni MP, Sampognaro S, Maggi E, Romagnani S, Trinchieri G. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. Journal of Experimental Medicine 1994; 179: 1273–1283
   PubMed Web of Science ®Google Scholar
• Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. Journal of Experimental Medicine 1993; 178: 1223–1230
   PubMed Web of Science ®Google Scholar
• Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, Hamilton TA. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. Journal of Immunology 1996; 156: 693–699
   PubMed Web of Science ®Google Scholar
• Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. Journal of the National Cancer Institute 1997; 89: 1049–1058
   PubMedGoogle Scholar
• Tahara H, Zeh HJ, 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Research 1994; 54: 182–189
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. Journal of Immunology 1995; 155: 1393–1403
   PubMed Web of Science ®Google Scholar
• Wu NZ, Klitzman B, Dodge R, Dewhirst MW. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Research 1992; 52: 4265–4268
   PubMed Web of Science ®Google Scholar
• Lohr F, Huang Q, Hu K, Dewhirst MW, Li CY. Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. Clinical Cancer Research 2001; 7: 3625–3628
   PubMed Web of Science ®Google Scholar
• Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, Dewhirst MW, Li CY. Enhancement of radiotherapy by hyperthermia-regulated gene therapy. International Journal of Radiation Oncology, Biology & Physics 2000; 48: 1513–1518
   PubMed Web of Science ®Google Scholar
• Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proceedings of the National Academy of Sciences (USA) 1998; 95: 2475–2480
   PubMed Web of Science ®Google Scholar
• Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang NS. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proceedings of the National Academy of Sciences (USA) 1996; 93: 6291–6296
   PubMed Web of Science ®Google Scholar
• Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: A review. Toxicology & Pathology 1999; 27: 58–63
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Feldmann M, Durum SK. Cytokine reference: a compendium of cytokines and other mediators of host defense. Academic Press, San Diego 2001
   Google Scholar
• Cohen J. IL-12 deaths: Explanation and a puzzle. Science 1995; 270: 908
   PubMed Web of Science ®Google Scholar
• Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzonie PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clinical Cancer Research 1997; 3: 409–417
   PubMed Web of Science ®Google Scholar
• Whitley D, Goldberg SP, Jordan WD. Heat shock proteins: a review of the molecular chaperones. Journal of Vascular Surgery 1999; 29: 748–751
   PubMed Web of Science ®Google Scholar
• Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochemistry & Biophysical Research Communications 2003; 304: 505–512
   PubMed Web of Science ®Google Scholar
• Nollen EA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing ‘heat shock’ proteins. Journal of Cell Science 2002; 115: 2809–2816
   PubMed Web of Science ®Google Scholar
• Morimoto RI, Tissiáeres A, Georgopoulos C. The biology of heat shock proteins and molecular chaperones. Cold Spring Harbor Laboratory Press, Plainview, NY 1994
   Google Scholar
• Borrelli MJ, Schoenherr DM, Wong A, Bernock LJ, Corry PM. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells. Cancer Research 2001; 61: 1113–1121
   PubMed Web of Science ®Google Scholar
• Li CY, Dewhirst MW. Hyperthermia-regulated immunogene therapy. International Journal of Hyperthermia 2002; 18: 586–596
   PubMed Web of Science ®Google Scholar
• Wang Q, Finer MH. Second-generation adenovirus vectors. Natural Medicine 1996; 2: 714–716
   PubMed Web of Science ®Google Scholar
• Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proceedings of the National Academy of Sciences (USA) 1994; 91: 4407–4411
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schneider RJ. Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation of the cytokeratin network. Journal of Virology 1994; 68: 2544–2555
   PubMed Web of Science ®Google Scholar
• He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences (USA) 1998; 95: 2509–2514
   PubMed Web of Science ®Google Scholar
• Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 1977; 36: 59–74
   PubMed Web of Science ®Google Scholar
• Leutenegger CM, Mislin CN, Sigrist B, Ehrengruber MU, Hofmann-Lehmann R, Lutz H. Quantitative real-time PCR for the measurement of feline cytokine mRNA. Veterinary Immunology & Immunopathology 1999; 71: 291–305
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402–408
   PubMed Web of Science ®Google Scholar
• Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 2001; 29: 45
   PubMed Web of Science ®Google Scholar
• Mivechi NF, Ouyang H, Monson JM, Hahn GM. Correlation of heat resistance and HSP-70A mRNA levels in human tumor cells measured by competitive quantitative polymerase chain reaction. International Journal of Radiation Oncology, Biology & Physics 1994; 30: 141–149
   PubMed Web of Science ®Google Scholar
• Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. International Journal of Hyperthermia 1995; 11: 459–488
   PubMed Web of Science ®Google Scholar
• Huang Q, Hu JK, Lohr F, Zhang L, Braun R, Lanzen J, Little JB, Dewhirst MW, Li CY. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Research 2000; 60: 3435–3439
   PubMed Web of Science ®Google Scholar
• Yamada H, Chen D, Monstein HJ, Hakanson R. Effects of fasting on the expression of gastrin, cholecystokinin, and somatostatin genes and of various housekeeping genes in the pancreas and upper digestive tract of rats. Biochemical and Biophysics Research Communications 1997; 231: 835–838
   PubMed Web of Science ®Google Scholar
• Foss DL, Baarsch MJ, Murtaugh MP. Regulation of hypoxanthine phosphoribosyltransferase, glyceraldehyde-3-phosphate dehydrogenase and beta-actin mRNA expression in porcine immune cells and tissues. Animals in Biotechnology 1998; 9: 67–78
   PubMed Web of Science ®Google Scholar
• Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of Molecular Endocrinology 2000; 25: 169–193
   PubMed Web of Science ®Google Scholar
• Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002; 3, RESEARCH0034
   PubMed Web of Science ®Google Scholar
• Coss RA, Storck CW, Daskalakis C, Berd D, Wahl ML. Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells. Molecular Cancer Therapy 2003; 2: 383–388
   PubMed Web of Science ®Google Scholar
• Harvey BG, Maroni J, O’Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Human Gene Therapy 2002; 13: 15–63
   PubMed Web of Science ®Google Scholar
• Gu W, Ogose A, Kawashima H, Ito M, Ito T, Matsuba A, Kitahara H, Hotta T, Tokunaga K, Hatano H, Morita T, Urakawa S, Yoshizawa T, Kuwano R, Endo N. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clinical Cancer Research 2004; 10: 3831–3838
   PubMed Web of Science ®Google Scholar
• Witlox MA, Van Beusechem VW, Grill J, Haisma HJ, Schaap G, Bras J, Van Diest P, De Gast A, Curiel DT, Pinedo HM, Gerritsen WR, Wuisman PI. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. Journal of Gene Medicine 2002; 4: 510–516
   PubMed Web of Science ®Google Scholar
• Graat HC, Wuisman PI, van Beusechem VW, Carette JE, Gerritsen WR, Bras J, Schaap GR, Kaspers GJ, Ogose A, Gu W, Kawashima H, Hotta T. Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses. Clinical Cancer Research 2005; 11: 2445–2447, author reply 2447–2448
   PubMed Web of Science ®Google Scholar
• Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Research 2002; 62: 3812–3818
   PubMed Web of Science ®Google Scholar
• Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Research 2001; 61: 6592–6600
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Journal of Virology 1998; 72: 9706–9713
   PubMed Web of Science ®Google Scholar
• Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research 1998; 58: 5738–5748
   PubMed Web of Science ®Google Scholar
• Li GC, He F, Shao X, Urano M, Shen L, Kim D, Borrrelli M, Leibel SA, Gutin PH, Ling CC. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Research 2003; 63: 3268–3274
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. International Journal of Radiation Oncology, Biology & Physics 1984; 10: 787–800
   PubMed Web of Science ®Google Scholar
• Xu L, Zhao Y, Zhang Q, Li Y, Xu Y. Regulation of transgene expression in muscles by ultrasound-mediated hyperthermia. Gene Therapy 2004; 11: 894–900
   PubMed Web of Science ®Google Scholar